Tau immunotherapy for Alzheimer's disease

被引：202

作者：

Pedersen, Jan Torleif ^{[1
]}

Sigurdsson, Einar M. ^{[2
,3
]}

机构：

[1] H Lundbeck & Co AS, Neurodegenerat, DK-2500 Valby, Denmark

[2] NYU, Sch Med, Dept Neurosci & Physiol, New York, NY 10016 USA

[3] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2015年 / 21卷 / 06期

关键词：

Alzheimer's disease; tauopathies; tau protein; immunotherapy; BRAIN INTERSTITIAL FLUID; MOUSE MODEL; PASSIVE-IMMUNIZATION; PHOSPHORYLATED TAU; NEUROFIBRILLARY TANGLES; IN-VITRO; PATHOLOGY; TAUOPATHY; ANTIBODY; PROTEIN;

D O I：

10.1016/j.molmed.2015.03.003

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeting pathological tau protein in Alzheimer's disease (AD) and related tauopathies has shown great potential in animal models. Given that tau lesions correlate better with the degree of dementia than do amyloid-beta (A beta) plaques, their clearance may be clinically more efficacious than removing A beta when cognitive deficits become evident in AD. Several complementary mechanisms of antibody-mediated removal of tau aggregates are likely to act in concert and the importance of each one may depend on antibody properties, the disease, and its stage. Clinical trials of tau immunotherapy are already underway and several more are likely to be initiated in the near future.

引用

页码：394 / 402

页数：9

共 98 条

[1] A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity [J].

Ahmed, Zeshan ;

Cooper, Jane ;

Murray, Tracey K. ;

Garn, Katya ;

McNaughton, Emily ;

Clarke, Hannah ;

Parhizkar, Samira ;

Ward, Mark A. ;

Cavallini, Annalisa ;

Jackson, Samuel ;

Bose, Suchira ;

Clavaguera, Florence ;

Tolnay, Markus ;

Lavenir, Isabelle ;

Goedert, Michel ;

Hutton, Michael L. ;

O'Neill, Michael J. .

ACTA NEUROPATHOLOGICA, 2014, 127 (05) :667-683

[2]

Allen B, 2002, J NEUROSCI, V22, P9340

[3]

Alzheimers Disease International & World Health Organization, 2015, Dementia: a public health priority, ISBN

[4] Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements [J].

Asuni, Ayodeji A. ;

Boutajangout, Allal ;

Quartermain, David ;

Sigurdsson, Einar M. .

JOURNAL OF NEUROSCIENCE, 2007, 27 (34) :9115-9129

[5] Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice [J].

Bi, Mian ;

Ittner, Arne ;

Ke, Yazi D. ;

Goetz, Juergen ;

Ittner, Lars M. .

PLOS ONE, 2011, 6 (12)

[6] Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice [J].

Boimel, Moran ;

Grigoriadis, Nikolaos ;

Lourbopoulos, Athanasios ;

Haber, Esther ;

Abramsky, Oded ;

Rosenmann, Hanna .

EXPERIMENTAL NEUROLOGY, 2010, 224 (02) :472-485

[7]

Boutajangout A, 2010, Alzheimers Dement, V4, pS578

[8] Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain [J].

Boutajangout, Allal ;

Ingadottir, Johanna ;

Davies, Peter ;

Sigurdsson, Einar M. .

JOURNAL OF NEUROCHEMISTRY, 2011, 118 (04) :658-667

[9] Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model [J].

Boutajangout, Allal ;

Quartermain, David ;

Sigurdsson, Einar M. .

JOURNAL OF NEUROSCIENCE, 2010, 30 (49) :16559-16566

[10]

Braak E, 1999, EUR ARCH PSY CLIN N, V249, P14

← 1 2 3 4 5 6 7 8 9 10 →